Literature DB >> 15142259

Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis.

Erik R Vossenaar1, Walther J van Venrooij.   

Abstract

Antibodies directed to citrullinated proteins (e.g. anti-CCP [cyclic citrullinated peptide] antibodies) are highly specific for rheumatoid arthritis (RA). These antibodies are produced at the site of inflammation in RA, and therefore citrullinated antigens are also expected to be present in the inflamed synovium. We discuss literature showing that the presence of citrullinated proteins in the synovium is not specific for RA. The RA-specific antibodies are therefore most likely the result of an abnormal immune response that specifically occurs in RA patients. It was recently shown that presence of anti-CCP antibodies precedes the onset of clinical symptoms of RA by years. It thus appears that it may take years for initial events that cause the generation of anti-CCP antibodies to develop into full-blown disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142259      PMCID: PMC416453          DOI: 10.1186/ar1184

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  36 in total

1.  Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes.

Authors:  Katsuhiko Nakashima; Teruki Hagiwara; Michiyuki Yamada
Journal:  J Biol Chem       Date:  2002-10-18       Impact factor: 5.157

2.  Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies.

Authors:  D Baeten; I Peene; A Union; L Meheus; M Sebbag; G Serre; E M Veys; F De Keyser
Journal:  Arthritis Rheum       Date:  2001-10

3.  Origin and significance of rice bodies in synovial fluid.

Authors:  D J McCarthy; H S Cheung
Journal:  Lancet       Date:  1982-09-25       Impact factor: 79.321

4.  Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis.

Authors:  C C Reparon-Schuijt; W J van Esch; C van Kooten; G A Schellekens; B A de Jong; W J van Venrooij; F C Breedveld; C L Verweij
Journal:  Arthritis Rheum       Date:  2001-01

5.  In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum.

Authors:  C Masson-Bessière; M Sebbag; J J Durieux; L Nogueira; C Vincent; E Girbal-Neuhauser; R Durroux; A Cantagrel; G Serre
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

6.  Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.

Authors:  Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Authors:  F A van Gaalen; S P Linn-Rasker; W J van Venrooij; B A de Jong; F C Breedveld; C L Verweij; R E M Toes; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2004-03

8.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

9.  Citrullination of synovial proteins in murine models of rheumatoid arthritis.

Authors:  Erik R Vossenaar; Suzanne Nijenhuis; Monique M A Helsen; Annemarie van der Heijden; Tatsuo Senshu; Wim B van den Berg; Walther J van Venrooij; Leo A B Joosten
Journal:  Arthritis Rheum       Date:  2003-09

Review 10.  Epidemiology and genetics of rheumatoid arthritis.

Authors:  Alan J Silman; Jacqueline E Pearson
Journal:  Arthritis Res       Date:  2002-05-09
View more
  74 in total

1.  Citrullination is an inflammation-dependent process.

Authors:  D Makrygiannakis; E af Klint; I E Lundberg; R Löfberg; A-K Ulfgren; L Klareskog; A I Catrina
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

2.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

Review 3.  Biological therapies directed against cells in autoimmune disease.

Authors:  Paul Hasler
Journal:  Springer Semin Immunopathol       Date:  2006-04-28

Review 4.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

5.  Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.

Authors:  Bryan Knuckley; Corey P Causey; Perry J Pellechia; Paul F Cook; Paul R Thompson
Journal:  Chembiochem       Date:  2010-01-25       Impact factor: 3.164

6.  Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study.

Authors:  So-Young Bang; Tae-Un Han; Chan-Bum Choi; Yoon-Kyoung Sung; Sang-Cheol Bae; Changwon Kang
Journal:  Arthritis Res Ther       Date:  2010-06-10       Impact factor: 5.156

7.  Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy.

Authors:  Wafaa M Ezzat; Hala M Raslan; Azza A Aly; Nahed A Emara; Manal M El Menyawi; Amr Edrees
Journal:  Rheumatol Int       Date:  2009-11-01       Impact factor: 2.631

Review 8.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

9.  Targeted therapies in rheumatoid arthritis: Focus on rituximab.

Authors:  Y K Teng; T W Huizinga; J M van Laar
Journal:  Biologics       Date:  2007-12

10.  Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis.

Authors:  Lan Shao; Hiroshi Fujii; Inés Colmegna; Hisashi Oishi; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Exp Med       Date:  2009-05-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.